...... A.i29 Nov 2023 08:10
1 Good to see ithe in depth presentation. (50 minutes) , had an initial listen and a good slide fron Peter which broken down the 36 project into various sections and that pipeline was £1mln and can be a "top up process" into this pot. He said there are 9 of these which are ready to be signed. He re iterated the information from the annual report that they are targeting their best ever revenues (£1.0mln+ ) having already secured about £300k since June 2023 and with Merck back on board in August 2023 whom accounted for 40% of previous revenues (therefore about £300-400k)
Also stated they would inform the market if these were to be beaten .
From annual report:
A) pipeline of potential new contracts that could start in the current financial year which remains at over £1m despite four opportunities having been converted into signed projects during August
B)We provide a responsive and dedicated service. Many large companies offer services in the cancer space though do not restrict themselves to cancer nor to quantitative pharmacology. As a result, we believe, many of these companies cannot offer the same level of bespoke, responsive service that Physiomics can and does.
C)The Company continues to work in the immuno-oncology space with several of its clients, and it is anticipated that the industry focus on this treatment approach is likely to continue for some time
2.Jim also mentioned that for the 1st time since Brexit 2016 UK companies like PYC cam now apply...in fact Jim said the recent project was via this route,he said clearly with dozens of countries being able to apply it is competitive but he seems hopeful of other projects
Details about Horizon below
Horizon Europe is an EU research and innovation programme. It has a budget of €95.5 billion and runs until 2027.
The UK agreed a deal to associate to Horizon Europe on 7 September 2023.
3 Also new office was to aid remote working,
Jim says should save £30k-40k per annum and will be reviewed
4 Also interesting was that he and now Pete mention Project Optimus/FDA modelling expectations in everyclient discussion
5. AI has also been found to be useful for increasing the chances of a new medicine being successful in treating patients
From PYC website regarding PYC A.I applications
Personalised Dosing Tool Development
Data Identification
Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria
AI & Machine Learning
Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy
Sign In
Follow the stocks
